Last quarter (Q4 2023), Cardiff Oncology's total revenue was $156.00K, an increase of 21.88% from the same quarter last year. In Q4, Cardiff Oncology's net income was $-9.34M. See Cardiff Oncology’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 488.00K	$ 488.00K	$ 386.00K	$ 359.00K	$ 366.00K	$ 244.63K
Cost of Revenue	-	-	-	-	-	$ 0.00
Gross Profit	$ 488.00K	$ 488.00K	$ 386.00K	$ 359.00K	-	$ 244.63K
Operating Expense	$ 45.90M	$ 45.90M	$ 40.29M	$ -29.21M	$ 19.45M	$ 16.92M
Operating Income	$ -45.41M	$ -45.41M	$ -39.90M	$ -28.86M	$ -19.09M	$ -16.68M
Net Non Operating Interest Income Expense	$ 4.07M	$ 4.07M	$ 1.58M	$ 264.00K	$ 88.00K	$ 234.17K
Other Income Expense	$ 98.00K	$ 98.00K	$ 383.00K	$ -300.00K	$ -309.00K	$ 30.17K
Pretax Income	$ -41.44M	$ -41.44M	$ -38.70M	$ -28.29M	$ -19.31M	$ -16.41M
Tax Provision	$ -9.09M	$ -9.09M	$ -518.00K	$ -72.00K	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -41.47M	$ -41.47M	$ -38.73M	$ -28.32M	$ -22.60M	$ -16.71M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 45.90M	$ 45.90M	$ 40.29M	$ -29.21M	$ 19.45M	$ 16.92M
Net Income From Continuing And Discontinued Operation	$ -41.44M	$ -41.44M	$ -38.70M	$ -28.29M	$ -19.31M	$ -16.41M
Normalized Income	$ -34.92M	$ -50.53M	$ -39.22M	-	$ -19.03M	$ -16.44M
Interest Expense	-	-	-	-	$ 2.00K	$ 0.00
EBIT	$ -41.44M	$ -41.44M	$ -38.70M	$ -28.29M	$ -19.30M	$ -16.41M
EBITDA	$ -41.96M	$ -41.96M	$ -37.84M	$ -26.23M	$ -18.84M	$ -15.92M

Currency in USD

Cardiff Oncology Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing